Record revenue of $12.3 million, increased 22% year over year
Progress on four success pillars, including 54% of revenue from recurring patient sources
Narrowing full-year revenue guidance to $46-47 million, at the upper end of previous guidance
Conference call begins at 4:30pm Eastern time today
BURLINGTON, Mass. (November 9, 2026) – Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2026.
“The focus on our four success pillars helped deliver record revenue and solid operating leverage in the quarter, resulting in breakeven Adjusted EBITDA and sequentially lower cash burn”, said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. “Third quarter revenue places us on track to achieve the midpoint or better of our raised guidance from last quarter. In addition, I am pleased to report that our MyoConnect program now exceeds 500 referral locations in the U.S., helping to drive revenue from recurring sources.” Read more.